Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.

RATIONALE The increasing worldwide incidence of extensively drug-resistant tuberculosis (XDR-TB) has emerged as a threat to public health and tuberculosis (TB) control. Treatment outcomes have varied among studies, and data on long-term survival are still scarce. OBJECTIVES To retrospectively assess the burden, clinical characteristics, treatment outcomes, and long-term survival rate of patients with XDR-TB in a cohort of patients with HIV-negative multidrug-resistant tuberculosis (MDR-TB) in South Korea. METHODS Medical records were reviewed of patients newly diagnosed with or retreated for MDR-TB from 2000 to 2002. The cohort was monitored for 3 to 7 years after the initiation of treatment. Initial treatment outcomes and cumulative survival rates were analyzed, and predictors of treatment success and survival were defined. MEASUREMENTS AND MAIN RESULTS Of 1,407 patients with MDR-TB 75 (5.3%) had XDR-TB at treatment initiation. The default rate was high (453/1,407; 32%), and patients with XDR-TB had lower treatment success (29.3 vs. 46.2%; P = 0.004) and higher all-cause (49.3 vs. 19.4%; P < 0.001) and TB-related disease mortality (41.3 vs. 11.8%; P < 0.001) than other patients with MDR-TB. The presence of XDR-TB significantly affected treatment success (odds ratio, 0.23; 95% confidence interval [CI], 0.08-0.64; P = 0.005), all-cause mortality (hazards ratio, 3.25; 95% CI, 1.91-5.53; P < 0.001), and TB-related mortality (hazards ratio, 4.45; 95% CI, 2.48-8.00; P < 0.001) on multivariate analyses. CONCLUSIONS XDR-TB occurred in a substantial proportion of patients with MDR-TB in South Korea, and was the strongest predictor of treatment outcomes and long-term survival in patients with MDR-TB. Adequate TB control policies should be implemented to prevent the further development and spread of drug resistance.

[1]  R. Koenig In South Africa, XDR TB and HIV Prove a Deadly Combination , 2008, Science.

[2]  J. Yim,et al.  Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  K. Kliiman,et al.  Clinical and operational value of the extensively drug-resistant tuberculosis definition , 2007, European Respiratory Journal.

[4]  G. Leung,et al.  Lower risk of tuberculosis in obesity. , 2007, Archives of internal medicine.

[5]  A. Gori,et al.  Extensively Drug-resistant Tuberculosis, Italy and Germany , 2007, Emerging infectious diseases.

[6]  G. Bai,et al.  Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  G. Bai,et al.  An Internet-based surveillance system for tuberculosis in Korea. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  D. Enarson,et al.  Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study , 2006, European Respiratory Journal.

[9]  S. M. Lee,et al.  Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis , 2006, European Respiratory Journal.

[10]  J. Mukherjee,et al.  Multidrug-resistant Tuberculosis Management in Resource-limited Settings , 2006, Emerging infectious diseases.

[11]  Mehran Hosseini,et al.  Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.

[12]  H S F Fraser,et al.  Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  M. H. Vargas,et al.  A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. , 2005, Chest.

[14]  E. Chan,et al.  Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[15]  S. K. Park,et al.  The treatment of tuberculosis in South Korea. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  W. Lew,et al.  Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  L. Karasulu,et al.  The treatment of multidrug-resistant tuberculosis in Turkey. , 2001, The New England journal of medicine.

[18]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[19]  M. Oh,et al.  Epidemiology of HIV infection in the Republic of Korea. , 1999, Journal of Korean medical science.

[20]  L. Ackerson,et al.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.

[21]  Lloyd N. Friedman,et al.  Diagnostic standards and classification of tuberculosis. , 1991, The American review of respiratory disease.

[22]  L. Tanoue,et al.  Tuberculosis in Africa — Combating an HIV-Driven Crisis , 2009 .

[23]  L. Tanoue Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2008 .

[24]  L. Tanoue Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis , 2008 .

[25]  S. Holland,et al.  Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  L. Tanoue Extensively Drug-Resistant Tuberculosis—United States, 1993–2006 , 2008 .

[27]  B. Choi Perspectives of Policies on HIV/AIDS and Tuberculosis Control in Korea. , 2006 .